LGD-3303 has been evaluated for muscle and bone effects in rats. It should not be confused with LGD-4033, which is a different molecule with a separate human evidence base.
Key points
- Rat pharmacokinetic studies suggest tissue-selective activity but cannot prove clinical safety.
- Bone findings come from osteopenic female-rat experiments.
- No controlled human efficacy study was identified for LGD-3303.
What the literature shows
Vajda and colleagues investigated LGD-3303 pharmacokinetics and pharmacodynamics in rats, comparing anabolic and androgenic tissue responses. Selectivity in those tissues under experimental conditions does not eliminate other potential harms.
A second rat study combined a SARM with a bisphosphonate in an osteopenia model. Combination effects on bone cannot be read as evidence for muscle gains or safety in healthy adults.
What remains unknown
- Human absorption, adverse-event frequency and long-term outcomes remain unknown.
- Whether retail products marketed as LGD-3303 match study material is unverified.
Safety and monitoring implications
- Do not transfer findings from LGD-4033 or from animal models to LGD-3303.
- Discuss unexpected endocrine symptoms, chest pain or liver-related symptoms with a qualified clinician.
Cited literature
- 1.Vajda EG, López FJ, Rix P, et al. (2009). Pharmacokinetics and pharmacodynamics of LGD-3303, an orally available nonsteroidal-selective androgen receptor modulator. Journal of Pharmacology and Experimental Therapeutics. Find on PubMed
- 2.Vajda EG, Hogue A, Griffiths KN, et al. (2009). Combination treatment with a selective androgen receptor modulator and a bisphosphonate has additive effects in osteopenic female rats. Journal of Bone and Mineral Research. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedNo independently verified community reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying LGD-3303 in Australia: what to check first
APEDRA does not sell LGD-3303 or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.